Article
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
The lancet. Gastroenterology & hepatology - 1 Jul 2020
Feld Jordan J, Cypel Marcelo, Kumar Deepali, Dahari Harel, Pinto Ribeiro Rafaela Vanin, Marks Nikki, Kamkar Nellie, Bahinskaya Ilona, Onofrio Fernanda Q, Zahoor Mohamed A, Cerrochi Orlando, Tinckam Kathryn, Kim S Joseph, Schiff Jeffrey, Reichman Trevor W, McDonald Michael, Alba Carolina, Waddell Thomas K, Sapisochin Gonzalo, Selzner Markus, Keshavjee Shaf, Janssen Harry L A, Hansen Bettina E, Singer Lianne G, Humar Atul
Abstract excerpt
BACKGROUND: An increasing percentage of potential organ donors are infected with hepatitis C virus (HCV). After transplantation from an infected donor, establishment of HCV infection in uninfected recipients is near-universal, with the requirement for post-transplant antiviral treatment. The aim of this study was to determine if antiviral drugs combined with an HCV entry blocker given before and for 7 days after...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.